| Fluorescence In-Situ Hybridization (FISH), Neoplastic Disorders (PDF version) |
| Neoplasm |
Cytogenetic Aberration/Locus |
Probe Name |
| Chronic Myeloproliferative Diseases |
| Chronic myelogenous leukemia |
t(9;22)(q34;q11.2) |
BCR/ABL
|
| Hypereosinophilic syndrome |
4q12 deletion
|
CHIC2
|
| Polycythemia vera |
t(9;22)(q34;q11.2) |
BCR/ABL
|
| Essential thrombocythemia |
t(9;22)(q34;q11.2) |
BCR/ABL
|
| Myelodysplastic/myeloproliferative diseases |
| Chronic myelomonocytic leukemia |
7cen |
D7Z1
|
| Juvenile myelomonocytic leukemia |
7cen |
D7Z1
|
| Myelodysplastic syndromes (MDS) |
MDS FISH Panel
(Probes can be ordered individually) |
5p15.2/5q31
|
D5S721, D5S23/EGR1 |
7q11.23/7q31
|
ELN, LIMK1, D7S613/ D7S486, D7S522 |
| 8cen |
D8Z2
|
| 20q12 |
D20S108
|
| 11q23 |
MLL
|
| Acute myeloid leukemia (AML) |
| AML, FAB type M2 |
t(8;21)(q22;q22) |
ETO/AML1
|
| Acute promyelocytic leukemia, FAB type M3 |
t(15;17)(q24;q21.1) and variants |
PML/RARα
|
| AML, FAB type M4eo |
inv(16)(p13q22) or t(16;16)(p13;q22) |
CBFβ |
| AML with 11q23 abnormalities |
11q23 |
MLL
|
| AML and MDS, therapy related: |
Alkylating Agent Related
|
5p15.2/5q31
|
D5S721, D5S23/EGR1
|
7q11.23/7q31
|
ELN, LIMK1, D7S613/ D7S486, D7S522
|
Topoisomerase II inhibitor-related
|
11q23
|
MLL
|
| Precursor B and T-cell Neoplasms |
Precursor B-lymphoblastic leukemia/lymphoma (ALL) FISH Panel
(Probes can be ordered individually) |
t(9;22)(q34;q11.2) |
BCR/ABL
|
| t(12;21)(p13;q22) |
TEL/AML1
|
| 11q23 rearrangement |
MLL
|
| 4cen/10cen/17cen |
D4Z1/D10Z1/D17Z1
|
| Precursor T-lymphoblastic leukemia/lymphoma |
9q34 |
ABL
|
| 9p21 |
p16
|
| Mature B-cell Neoplasms |
Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) FISH Panel
(Probes can be ordered individually) |
11q22.3 |
ATM
|
| 12cen |
D12Z3
|
| 13q14 |
RB1
|
| 17p13.1 |
TP53
|
| Multiple myeloma (MM) FISH Panel (Probes can be ordered individually) |
3cen |
D3Z1
|
| 9cen |
D9Z1
|
| t(11;14)(q13;q32) |
CCND1(BCL1)/IGH
|
| 13q14 |
RB1
|
| 17p13.1 |
TP53
|
| Extranodal marginal zone B-cell lymphoma (MALT lymphoma) |
t(11;18)(q21;q21) |
API2/MALT1
|
| Follicular lymphoma |
t(14;18)(q32;q21) |
IGH/BCL2
|
| Mantle cell lymphoma |
t(11;14)(q13;q32) |
CCND1(BCL1)/IGH
|
| Diffuse large B-cell lymphoma |
3q27 |
BCL6
|
| Burkitt lymphoma/leukemia |
t(8;14)(q24.1;q32) and variants |
CMYC/IGH
|
| Mature T-cell and NK-cell Neoplasms |
| Anaplastic large cell lymphoma |
t(2;5)(p23;q35) and variants |
ALK
|
| Mastocytosis |
| Systemic mastocytosis |
4q12 deletion |
CHIC2
|
| Solid Tumors |
| Alveolar Rhabdomyosarcoma |
t(2;13)(q35;q14) and variants |
FKHR
|
| Ewing Sarcoma |
t(11;22)(q24;q12) and variants |
EWSR1
|
| Myxoid Liposarcoma |
t(12;16)(q13;p11.2) |
FUS
|
| Neuroblastoma |
2p23-24 |
NMYC
|
| Synovial Sarcoma |
t(X;18)(p11.2;q11.2) |
SYT
|
